Evaluation of RNA Based Biomarker Expression in Acute Kidney Injury after ESWL

Abstract

xtracorporeal shock wave lithotripsy (ESWL) was introduced more than three decades as an authentic modern modality for the treatment of urinary stone disease. It is considered first choice of treatment for nearly all kinds of urinary tract calculi. Since its appearance at the beginning of the 1980s, extracorporeal shock wave lithotripsy (ESWL) has been confirmed as the least invasive and the most widely used treatment of kidney and ureteral stones Naturally, like any other treatment, its efficacy is indeed accompanied by some side effects and complications that, despite being generally mild in nature, require accurate evaluation and implementation of measures to prevent them. The European Association of Urology (EAU) guidelines recommend the use of less invasive modalities such as extracorporeal shockwave lithotripsy (ESWL) for stones less than 2 cm. Complications after ESWL are mainly connected to the formation and passage of fragments, infections, the effects on renal and nonrenal tissues, and the effects on kidney function. Long non-coding RNAs (lncRNAs) plays an important role in the development of many renal diseases. It have been discovered that lncRNAs are involved in kidney development and that their dysregulation can result in distinct disease processes, including acute kidney injury (AKI) and chronic kidney disease (CKD).